4-环丙基-2-(甲基硫代)嘧啶-5-羧酸乙酯 | 1191094-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-环丙基-2-(甲基硫代)嘧啶-5-羧酸乙酯
• 英文名称: ethyl 4-cyclopropyl-2-(methylthio)pyrimidine-5-carboxylate
• 英文别名: ethyl 4-cyclopropyl-2-methylsulfanylpyrimidine-5-carboxylate
• CAS: 1191094-23-1
• 化学式: C₁₁H₁₄N₂O₂S
• 分子量: 238.31
• InChiKey: JWQNZVNBLPBLTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  77.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-环丙基-2-(甲基硫代)嘧啶-5-羧酸乙酯 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以87%的产率得到4-cyclopropyl-2-(methylthio)pyrimidine-5-carboxylic acid
  参考文献：
  名称：

  SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281

  摘要：

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。

  公开号：

  US20090264401A1
• 作为产物：
  描述：

  3-环丙基-3-羰基-丙酸乙酯 在 sodium acetate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 4-环丙基-2-(甲基硫代)嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  Free-Wilson and Structural Approaches to Co-optimizing Human and Rodent Isoform Potency for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors

  摘要：

  11 beta-Hydroxysteroid dehydrogenase 1 (11 beta-HSD1) has been a target of intensive research efforts across the pharmaceutical industry, due to its potential for the treatment of type II diabetes and other elements of the metabolic syndrome. To demonstrate the value of 11 beta-HSD1 in preclinical models, we required inhibitors with good potency against both human and rodent isoforms. Herein, we describe our efforts to understand how to co-optimize human and murine potency within the (5-hydroxy-2-adamantyl)-pyrimidine-5-carboxamide series. Two approaches are described a data-driven (Free-Wilson) analysis and a structure-based design approach. The conclusions from these approaches were used to inform an efficient campaign to design compounds with consistently good human/murine potency within a logD(7.4) range of 1-3. Compounds 20 and 26 demonstrated good rodent PK, which allowed us to demonstrate a PK/PD relationship in rat and mouse. We then evaluated 26 against glycemic and body weight end points in murine disease models, where it demonstrated glucose and body weight efficacy at 300 mg/kg/day but only body weight efficacy at 50 mg/kg/day, despite providing >90% target engagement in the liver.

  DOI：

  10.1021/jm3013163

文献信息

• Dual Photoredox/Nickel-Promoted Alkylation of Heteroaryl Halides with Redox-Active Esters
  作者：Nicole Erin Behnke、Zachary S. Sales、Minyan Li、Aaron T. Herrmann

  DOI：10.1021/acs.joc.1c01625

  日期：2021.9.17

  Herein a method for the radical alkylation of heteroaryl halides that relies upon the combination of photoredox and nickel catalysis is described. The use of aliphatic N-(acyloxy)phthalimides as redox-active esters affords primary and secondary radicals for the decarboxylative dual cross-coupling with pyrimidine and pyridine heteroaryl chlorides, bromides, and iodides. The method provides an additional

  本文描述了一种依赖于光氧化还原和镍催化组合的杂芳基卤化物的自由基烷基化方法。使用脂肪族N -（酰氧基）邻苯二甲酰亚胺作为氧化还原活性酯，为与嘧啶和吡啶杂芳基氯化物、溴化物和碘化物的脱羧双重交叉偶联提供伯基和仲基。该方法为纳入医学相关的杂环基序提供了一种额外的合成工具。
• [EN] SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281<br/>[FR] PYRIMIDINE-5-CARBOXAMIDES SUBSTITUÉS
  申请人：ASTRAZENECA AB

  公开号：WO2009130496A1

  公开（公告）日：2009-10-29

  A compound of formula (I) and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.
• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• Free-Wilson and Structural Approaches to Co-optimizing Human and Rodent Isoform Potency for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors
  作者：Frederick W. Goldberg、Andrew G. Leach、James S. Scott、Wendy L. Snelson、Sam D. Groombridge、Craig S. Donald、Stuart N. L. Bennett、Cristian Bodin、Pablo Morentin Gutierrez、Amy C. Gyte

  DOI：10.1021/jm3013163

  日期：2012.12.13

  11 beta-Hydroxysteroid dehydrogenase 1 (11 beta-HSD1) has been a target of intensive research efforts across the pharmaceutical industry, due to its potential for the treatment of type II diabetes and other elements of the metabolic syndrome. To demonstrate the value of 11 beta-HSD1 in preclinical models, we required inhibitors with good potency against both human and rodent isoforms. Herein, we describe our efforts to understand how to co-optimize human and murine potency within the (5-hydroxy-2-adamantyl)-pyrimidine-5-carboxamide series. Two approaches are described a data-driven (Free-Wilson) analysis and a structure-based design approach. The conclusions from these approaches were used to inform an efficient campaign to design compounds with consistently good human/murine potency within a logD(7.4) range of 1-3. Compounds 20 and 26 demonstrated good rodent PK, which allowed us to demonstrate a PK/PD relationship in rat and mouse. We then evaluated 26 against glycemic and body weight end points in murine disease models, where it demonstrated glucose and body weight efficacy at 300 mg/kg/day but only body weight efficacy at 50 mg/kg/day, despite providing >90% target engagement in the liver.